(RTTNews) - ALX Oncology Holdings Inc. (ALXO), a biopharmaceutical company focused on oncology treatments, has announced a workforce reduction of approximately 30% as part of its strategy to ...

ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker evorpacept and planned entry into the clinic of its novel ...

ALX Oncology stock opened at $1.03 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. ALX Oncology has a 52 week low of $0.96 and a 52 ...